IDEXX Laboratories (NASDAQ:IDXX) had its price objective boosted by Stifel Nicolaus from $280.00 to $375.00 in a report published on Thursday, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the stock.
IDXX has been the subject of several other research reports. Bank of America increased their target price on IDEXX Laboratories from $300.00 to $390.00 and gave the stock a buy rating in a research report on Monday, July 20th. BidaskClub lowered IDEXX Laboratories from a strong-buy rating to a buy rating in a research report on Saturday, June 6th. Finally, TheStreet raised IDEXX Laboratories from a c+ rating to a b- rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $317.14.
IDXX traded up $23.65 during midday trading on Thursday, reaching $397.75. 783,280 shares of the company’s stock traded hands, compared to its average volume of 327,199. The firm has a fifty day moving average of $335.38 and a two-hundred day moving average of $286.60. The stock has a market capitalization of $33.78 billion, a price-to-earnings ratio of 79.55, a P/E/G ratio of 6.12 and a beta of 0.81. The company has a debt-to-equity ratio of 7.06, a current ratio of 0.85 and a quick ratio of 0.60. IDEXX Laboratories has a 52 week low of $168.65 and a 52 week high of $407.86.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, July 31st. The company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.55. IDEXX Laboratories had a return on equity of 264.71% and a net margin of 17.78%. The firm had revenue of $637.20 million during the quarter, compared to analyst estimates of $589.98 million. During the same quarter in the prior year, the company earned $1.43 EPS. The business’s revenue was up 2.8% compared to the same quarter last year. Sell-side analysts forecast that IDEXX Laboratories will post 5.09 EPS for the current year.
In related news, Director Rebecca M. Henderson sold 13,396 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $286.66, for a total value of $3,840,097.36. Following the sale, the director now owns 20,670 shares in the company, valued at approximately $5,925,262.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 7,722 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $306.91, for a total value of $2,369,959.02. Following the completion of the sale, the director now owns 7,722 shares in the company, valued at approximately $2,369,959.02. The disclosure for this sale can be found here. Insiders sold a total of 106,182 shares of company stock worth $31,409,008 in the last 90 days. 2.53% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of IDXX. Sound Income Strategies LLC boosted its stake in IDEXX Laboratories by 189.1% during the 1st quarter. Sound Income Strategies LLC now owns 133 shares of the company’s stock valued at $32,000 after purchasing an additional 87 shares during the last quarter. Key Financial Inc purchased a new position in shares of IDEXX Laboratories in the 1st quarter worth $36,000. Anderson Fisher LLC purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth $36,000. Tompkins Financial Corp purchased a new position in shares of IDEXX Laboratories in the 1st quarter worth $38,000. Finally, Carroll Financial Associates Inc. boosted its stake in shares of IDEXX Laboratories by 645.8% in the 1st quarter. Carroll Financial Associates Inc. now owns 179 shares of the company’s stock worth $43,000 after buying an additional 155 shares during the last quarter. Institutional investors and hedge funds own 88.58% of the company’s stock.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: How to use beta for portfolio diversification
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.